Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25905037 | 0.84 | CYP3A4 (0.34) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL7665646 | 0.79 | CYP3A4 (0.45) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL11900495 | 0.79 | CYP3A4 (0.45) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| Hydrochloric Acid SCHEMBL28527606 | 0.78 | CYP3A4 (0.44) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL3749196 | 0.77 | CYP11B1 (0.43) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL23540359 | 0.76 | KIF11 (0.51) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL30595619 | 0.76 | KIF11 (0.51) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL30042197 | 0.76 | KIF11 (0.51) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 | |
| SCHEMBL998165 | 0.75 | IDO1 (0.46) | IDO1ALDH1A1P2RX1 | |
| SCHEMBL17700603 | 0.75 | CYP3A4 (0.42) | CYP3A4CYP2C9SLC22A6SLC22A8SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119113123-A | Method for treating or preventing diabetes mellitus by using combination drug | 日本烟草产业株式会社 | 2024-12-13 | — | — | CN | disclosed |
| CN-114585387-B | Method for treating or preventing diabetes mellitus by using combination drug | 日本烟草产业株式会社 | 2024-10-29 | — | — | CN | disclosed |
| CN-114641314-B | Method for treating or preventing chronic kidney disease | 日本烟草产业株式会社 | 2024-05-28 | — | — | CN | disclosed |
| US-20240166632-A1 | PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2024-05-23 | — | — | US | disclosed |
| EP-4342466-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | Japan Tobacco Inc. (JP) | 2024-03-27 | — | — | EP | disclosed |
| CN-111902408-B | Heteroaryl substituted pyrazole compounds and pharmaceutical uses thereof | 日本烟草产业株式会社 | 2023-11-14 | — | — | CN | disclosed |
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | JAPAN TOBACCO INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | JAPAN TOBACCO INC. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | JAPAN TOBACCO INC. (JP) | 2023-04-20 | — | — | US | disclosed |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | JAPAN TOBACCO INC. (JP) | 2023-04-20 | — | — | US | disclosed |
| WO-2021045161-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | 日本たばこ産業株式会社 | 2021-03-11 | — | — | WO | disclosed |
| WO-2021045161-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | 日本たばこ産業株式会社 | 2021-03-11 | — | — | WO | disclosed |
| EP-3778593-A1 | HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778593-A1 | HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-02-17 | — | — | EP | disclosed |
| CN-111902408-A | Heteroaryl-substituted pyrazole compounds and pharmaceutical use thereof | 日本烟草产业株式会社 | 2020-11-06 | — | — | CN | disclosed |
| US-20190330193-A1 | PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-10-31 | — | — | US | disclosed |
| US-20190330193-A1 | PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2019-10-31 | — | — | US | disclosed |
| WO-2019194207-A1 | HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND MEDICINAL USE THEREOF | 日本たばこ産業株式会社 | 2019-10-10 | — | — | WO | disclosed |
| WO-2019194207-A1 | HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND MEDICINAL USE THEREOF | 日本たばこ産業株式会社 | 2019-10-10 | — | — | WO | disclosed |
| US-4775762-A | INSECTICIDES | THE DOW CHEMICAL COMPANY (US) | 1988-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330193-A1 | PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SULT2A1 | CYP3A4 138/4885CYP2C9 157/4885SLC22A6 128/4885 |
| US-20240166632-A1 | PYRAZOLE COMPOUNDS SUBSTITUTED WITH HETEROARYL AND PHARMACEUTICAL USE THEREOF | SLC5A1, SLC5A2, SULT2A1 | CYP3A4 138/4885CYP2C9 157/4885SLC22A6 128/4885 |
| US-20230210831-A1 | CHRONIC KIDNEY DISEASE TREATMENT OR PREVENTION METHOD | SLC5A1, SLC5A2, REN | CYP3A4 3621/4885CYP2C9 2248/4885SLC22A6 60/4885 |
| US-20230119894-A1 | THERAPEUTIC OR PROPHYLACTIC METHOD FOR DIABETES USING COMBINATION MEDICINE | DPP4, SLC5A1, SLC5A2 | CYP3A4 377/4885CYP2C9 1272/4885SLC22A6 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.